A Phase I Study of 225Ac-Lintuzumab in Patients With Multiple Myeloma Progressing After . 3 Prior Anti-MM Regimens or Refractory to QUAD (Carfilzomib, Lenalidomide, Pomalidomide, and Dexamethasone)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

22 Feb 2022 Status changed from active, no longer recruiting to discontinued.
22 May 2020 Status changed from recruiting to active, no longer recruiting.
03 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com